Corporate video
At a glance
VHIO talents: accelerating cancer discovery through team science
PROFESSIONALS
RESEARCH GROUPS
including 8 new groups in 2023
Multidisciplinary task forces
transversal clinical trial core services/units
ONGOING RESEARCH PROJECTS
INSTITUTIONAL PROGRAMS:
CaixaResearch Advanced Oncology Research Program
BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI)
Molecular prescreening powered by our Advanced Molecular Diagnostics Program (DIAMAV)
Center of Excellence Severo Ochoa
Asociación Española Contra el Cáncer – AECC (Spanish Association Against Cancer) Excellence Program – Advanced Therapies Accelerator Program
Our preclinical and clinical researchers, oncologists, nursing staff and research support professionals, located at VHIO and the Vall d’Hebron University Hospital, work as closely connected teams to develop and advance new diagnostic tools and more effective therapeutics against cancer
Scientific productivity 2023
published research articles
Median impact factor
Clinical trials at VHIO
More than
patients included
in
clinical trials and studies with active recruitment at some time in the year
clinical trials are early phase studies at our Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch
Clinical trials and studies with active recruitment at some time in the year in oncology, hematology and radiotherapy:
Phase I trials
Basket trials
Phase II trials
Phase III trials
Post-authorization and rollover studies
Medical device trials
Since VHIO was established in 2006, our teams have contributed to more than 50 new drug indications.
203 new trials were initiated in 2023, including 22 post-authorization trials and rollover studies.
Technology transfer to-date, development of new therapies & technologies in precision oncology
patent families
4 Spin-off companies:
A phase II trial is evaluating Mosaic Anti-LIF antibody MSC-1,now AZD0171, has completed recruitment. Opened this year, a new phase II trial is testing this compound in small-cell lung cancer.
OMO-103 direct MYC-inhibitor successfully completed phase I clinical trial. A phase Ib trial for metastatic pancreatic cancer is underway.
HER2DX® assay launched as a new diagnostic tool for early-stage HER2+ breast cancer and recognized by TIME Magazine as one of the best inventions in 2022.
First-in-class TET2 modulator ONR-001 in preclinical development. The spin-off has successfully raised its seed funding round.
raised by VHIO’s Spin-off
jobs generated
More than
patients treated with VHIO derived therapies
advanced therapies developed in-house: p95HER2 CAR-T and NextGen-TIL-ACT.
Co-developed with third parties RAD51 predict as a new assay to identify patients who could benefit from PARP inhibitors, now used in a prospective clinical trial.
VHIO 360:
Liquid biopsy test based on Guardant360® technology
Comprehensive genomic profiling of 74 cancer-associated genes
First test in Europe based on this cutting-edge technology
New technologies, platforms and facilities 2023
UNIQUE CaixaResearch next-generation single-cell sequencing platform
Opera Phenix™ High Content Screening (HCS)
Advanced Therapies Accelerator Unit – Clean Room
Renovation of the first floor of our CELLEX Building providing 900 m2 for our 8 new research groups
New premises spanning a total surface area of 900.5 m2,
dedicated to innovation and technology/bioinformatics at VHIO
Cross-border consortia & partnerships of excellence
More than
European and international consortia, collaborations, and alliances of excellence in oncology (co) led by VHIO investigators
Education and training 2023
VHIO - CaixaResearch Scientific Seminars in 2023
Coordinated by the VHIO Academy, the VHIO – CaixaResearch Scientific Seminars Series welcomes internationally renowned researchers and clinical investigators to share and discuss their latest research findings and to meet with VHIO investigators.
1st VHIO-BBVA Foundation International Symposium on Cell-based Therapies in Oncology
This symposium provided an outstanding forum to present and the very latest developments in the field of advanced cell therapies, and to foster collaboration among leading, international experts.
In addition to coordinating the VHIO – CaixaResearch Scientific Seminars in 2023, the VHIO Academy, which is part of our Scientific Management Area, also organized:
academic programs
scientific and transferable skills trainings
workshops on professional development skills for clinicians
Cancer Core Europe (CCE) educational activities
The mission of the VHIO Academy is to attract and train the next generation of scientific leaders in oncology. Since its creation, VHIO Academy has achieved several highlights including the launch of international Academic Programs (Bachelor, Master, PhD calls), the implementation of a structured International PhD Program and the deployment of an Advanced Training Program.
Benchstormings in 2023
Our annual series of preclinical, translational and clinical Benchstorming Seminars represent an excellent platform for our junior faculty to present and discuss their research interests with other VHIO groups.
ad-hoc events in 2023
We also share our expertise, learn from eminent guest speakers, discuss, and debate our latest findings through the organization of VHIO ad-hoc courses and workshops.
Patient engagement events, fundraising, and public outreach activities
More than
VHIO (co) organized/hosted patient engagement events, fundraising and public outreach activities in 2023
VHIO Talks involving 10 patients, 20 investigators reaching 400 attendees
Research Day for patient associations of breast cancer, gathering 8 associations, 5 investigators and +50 PARTICIPANTS
Recognition through accreditation
VHIO continues to meet the high standards in quality and procedures in the audit of our Clinical Trials Units, carried out by the Generalitat de Catalunya (Government of Catalonia).
EuropeanSince 2020 VHIO and the Vall d’Hebron University Hospital are jointly accredited as a European Neuroendocrine Tumor Society (ENETS) Center of Excellence.
Accreditation with maximal distinction -A- from the Institució CERCA – Centres de Recerca de Catalunya (CERCA Institute of Research Centres of Catalonia) for the period 2017-2021 (‘A’ ranking).
Since 2022 VHIO is accredited as a Severo Ochoa Center of Excellence (2022-2026). This prestigious distinction is granted within the subprogram of the Spanish Institutional Strengthening of the State Plan for Scientific and Technical Research & Innovation.
Announced in 2022, and now launched as one of VHIO’s Institutional Programs, we received the support from the Asociación Española Contra el Cáncer – AECC (Spanish Association Against Cancer) Excellence Program – Advanced Therapies Accelerator Program.
